Courtesy of wyattiamrolling:
https://painkiller.care/
GEMINI says:
The website painkiller.care serves as a direct-to-consumer digital storefront and educational hub for ActiPatch®, the flagship product of BioElectronics Corp (BIEL).
The relationship between the site and the company is essentially that of a primary retail gateway. Here is how it impacts BioElectronics Corp:
1. Direct Sales & Revenue Growth
Retail Engine: The site is the primary "Buy Now" destination for ActiPatch. By controlling this platform, BIEL can capture higher margins compared to third-party retail or wholesale distribution.
Trial Programs: BIEL often uses direct sites like this to run "7-day trial" programs (a key part of their marketing strategy). These trials have historically converted over 80% of users into repeat purchasers, providing a steady revenue stream.
2. Market Expansion & Branding
Targeted Outreach: The URL itself is a "category-killer" domain designed to capture search traffic from people looking for general pain relief (analgesics) and pivoting them toward BIEL’s non-drug, electromagnetic pulse therapy.
Educational Authority: The site helps overcome the "education gap" for their Pulsed Shortwave Therapy (PSWT). Since PSWT is sensation-free (unlike TENS machines), the website acts as a necessary tool to explain the science of central sensitization and neuromodulation to skeptics.
3. Shift in North American Strategy
ActiPatch Focus: Interestingly, while BIEL signed a major OEM agreement with KT Health to market the technology as KT Recovery+ Wave™ (effectively phasing out the "ActiPatch" name in many big-box retail aisles), painkiller.care keeps the original ActiPatch brand alive and accessible for the niche, loyal customer base and international buyers.
4. Clinical Evidence Pipeline
Data Collection: BIEL uses its direct-to-consumer platforms to gather user-reported outcomes. Data from thousands of users visiting such sites has been used in their clinical submissions to the FDA and in peer-reviewed journals, helping them secure expanded clearances for conditions like osteoarthritis and plantar fasciitis.
Summary for Investors/Users:
If you see increased traffic or marketing spend on painkiller.care, it typically signals a push by BioElectronics Corp to increase their "DTC" (Direct-to-Consumer) footprint, which is their most profitable sales channel compared to their international distribution contracts.
https://painkiller.care/
GEMINI says:
The website painkiller.care serves as a direct-to-consumer digital storefront and educational hub for ActiPatch®, the flagship product of BioElectronics Corp (BIEL).
The relationship between the site and the company is essentially that of a primary retail gateway. Here is how it impacts BioElectronics Corp:
1. Direct Sales & Revenue Growth
Retail Engine: The site is the primary "Buy Now" destination for ActiPatch. By controlling this platform, BIEL can capture higher margins compared to third-party retail or wholesale distribution.
Trial Programs: BIEL often uses direct sites like this to run "7-day trial" programs (a key part of their marketing strategy). These trials have historically converted over 80% of users into repeat purchasers, providing a steady revenue stream.
2. Market Expansion & Branding
Targeted Outreach: The URL itself is a "category-killer" domain designed to capture search traffic from people looking for general pain relief (analgesics) and pivoting them toward BIEL’s non-drug, electromagnetic pulse therapy.
Educational Authority: The site helps overcome the "education gap" for their Pulsed Shortwave Therapy (PSWT). Since PSWT is sensation-free (unlike TENS machines), the website acts as a necessary tool to explain the science of central sensitization and neuromodulation to skeptics.
3. Shift in North American Strategy
ActiPatch Focus: Interestingly, while BIEL signed a major OEM agreement with KT Health to market the technology as KT Recovery+ Wave™ (effectively phasing out the "ActiPatch" name in many big-box retail aisles), painkiller.care keeps the original ActiPatch brand alive and accessible for the niche, loyal customer base and international buyers.
4. Clinical Evidence Pipeline
Data Collection: BIEL uses its direct-to-consumer platforms to gather user-reported outcomes. Data from thousands of users visiting such sites has been used in their clinical submissions to the FDA and in peer-reviewed journals, helping them secure expanded clearances for conditions like osteoarthritis and plantar fasciitis.
Summary for Investors/Users:
If you see increased traffic or marketing spend on painkiller.care, it typically signals a push by BioElectronics Corp to increase their "DTC" (Direct-to-Consumer) footprint, which is their most profitable sales channel compared to their international distribution contracts.
1
